Climb Bio Inc Cash Flow Conversion Efficiency
Climb Bio Inc cash flow conversion efficiency. Based on the latest financial reports, Climb Bio Inc (CLYM) has a cash flow conversion efficiency ratio of -0.044x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.55 Million) by net assets ($239.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Climb Bio Inc (2019–2025)
Cash flow conversion efficiency of Climb Bio Inc from 2019 to 2025. This chart illustrates how Climb Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CLYM stock price for real-time trading data and today's change.
Climb Bio Inc Cash Flow Conversion Ratio Explained
Climb Bio Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Climb Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Climb Bio Inc ranked by their cash flow conversion efficiency. Also see CLYM stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Stylam Industries Limited
NSE:STYLAMIND
|
0.104x |
|
Grupo Supervielle S.A. B
BA:SUPV
|
0.176x |
|
Qingdao Liqun Department Store Group Co Ltd
SHG:601366
|
0.146x |
|
Columbus McKinnon Corporation
NASDAQ:CMCO
|
0.019x |
|
Sawit Sumbermas Sarana Tbk
JK:SSMS
|
-0.225x |
|
Esso S.A.F.
PA:ES
|
-0.040x |
|
Foshan Nationstar Optoelectronics Co Ltd
SHE:002449
|
0.024x |
|
ZimVie Inc
NASDAQ:ZIMV
|
0.008x |
Annual Cash Flow Conversion Efficiency for Climb Bio Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Climb Bio Inc from 2019 to 2025. Review CLYM free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $160.47 Million | $-54.36 Million | -0.339x | -361.18% |
| 2024-12-31 | $211.88 Million | $-15.56 Million | -0.073x | +61.63% |
| 2023-12-31 | $107.60 Million | $-20.60 Million | -0.191x | +34.06% |
| 2022-12-31 | $128.72 Million | $-37.37 Million | -0.290x | -34.57% |
| 2021-12-31 | $167.20 Million | $-36.07 Million | -0.216x | +67.00% |
| 2020-12-31 | $21.57 Million | $-14.10 Million | -0.654x | -169.03% |
| 2019-12-31 | $20.61 Million | $-5.01 Million | -0.243x | -- |
About Climb Bio Inc
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary me… Read more